Heads up: some links below are affiliate links — assume any provider we list may compensate us, at no cost to you. It never buys a better score, but the providers we work with are listed first. See our affiliate disclosure.
Alternatives · ranked for speed
LeanDose lands at #279 on our ranking with a Rx-Readiness Score of 43/100. If it isn't the right fit, here are the strongest alternatives on our shortlist — scored on the same readiness rubric of speed to first dose, flat pricing, no-video signup, access, molecule choice and a clean off-ramp.
Top alternative
A flat $239/mo semaglutide, $399/mo tirzepatide, no-video intake with free overnight shipping — but it's only live in 23 states, and most big population centers aren't on the list.
Ranked #6 · Grade B
A flat $179 for either molecule with a genuinely gentle microdosing tier — a reasonable, all-doses-included partner if you can live with a yearly plan and a pharmacy it doesn't name.
Ranked #67 · Grade C
A no-membership-fee, quarterly-billed program — $167/mo semaglutide, $267/mo tirzepatide — bundling a GLP-1 fitness app, meal plans, and 1-on-1 nutrition coaching that most compounded-only competitors don't offer. It also publishes its own named comparison against Ro, Mochi Health, TrimRx, and Hims, an unusually direct move for this category.
Ranked #135 · Grade C
The lowest medication price on this roster, and a headline that still leaves out a required charge. Compounded semaglutide is $59 a month and tirzepatide $69, flat at every dose and cancellable at any time — both requiring a $199 annual membership the pricing line never mentions. Counted properly the first year is $907 for semaglutide, about $76 a month, and $1,027 for tirzepatide, about $86, which remains among the cheapest anywhere even after the fee. It is operated by Health For Everyone Inc., trading as CollectiveOS, and positioned on being brought to you by the founder of Thrive Market and on GLP-1s without the 500% markup. There is a 21-day free trial before the membership charge, after which the fee is non-refundable with no partial periods returned. The compounding pharmacies are never named, no state list is published, and no time to first dose is given.
Ranked #104 · Grade C
A one-product shop — compounded tirzepatide microdosing only, $89 the first month then $199/mo all-in, no live video visit described anywhere in the flow, and unusually candid on-site that the trial evidence for microdosing specifically is thin — but there's no semaglutide option at all, and no individual physician, pharmacy, or state list named anywhere on the site checked.
Ranked #88 · Grade C
A 3-month starter-bundle model — $99/mo semaglutide, $133/mo tirzepatide, medication plus shipping, consult and an injection kit included — serving all 50 states with no membership fees.
Ranked #168 · Grade C
A cardiometabolic telehealth platform built around diabetes care that also treats obesity — $149/mo self-pay or free with insurance, one price covering brand GLP-1s, labs, devices and a real multi-disciplinary care team, though it publishes no state list at all.
Ranked #108 · Grade C
A sublingual (under-the-tongue), not injectable, GLP-1 program — $189/mo semaglutide and $319/mo tirzepatide on a 6-month prepay plan, $209/mo and $359/mo on a shorter 2-month plan — serving 34 states plus DC.
Ranked #256 · Grade C
The cheapest sticker price reviewed — $100/mo semaglutide, $133/mo tirzepatide on the 3-month plans — but it requires a live video consult, names no pharmacy, and discloses no state list, which costs it on the exact factors that matter to a working mom's calendar.
Ranked #208 · Grade C
Cheap headline numbers — $133/mo semaglutide, $166/mo tirzepatide — inside a men's-longevity brand with no visible entrance for women, a 3-month minimum commitment, and a LegitScript badge technically attached to a different domain.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Rx-Readiness Score. Scores are our editorial judgment per the methodology. Not medical advice; see our disclosure.